BioAffinity Technologies Change in Accounts Payable 2022-2025 | BIAF

BioAffinity Technologies change in accounts payable from 2022 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

BioAffinity Technologies Change in Accounts Payable 2022-2025 | BIAF

BioAffinity Technologies change in accounts payable from 2022 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$248.3B
Amgen (AMGN)$155.9B
Gilead Sciences (GILD)$142.4B
Vertex Pharmaceuticals (VRTX)$99.3B
Bristol Myers Squibb (BMY)$96.1B
GSK (GSK)$81.1B
CSL (CSLLY)$67.7B
Regeneron Pharmaceuticals (REGN)$62.3B
Alnylam Pharmaceuticals (ALNY)$59.1B
Argenex SE (ARGX)$43.3B
Insmed (INSM)$27.9B
BioNTech SE (BNTX)$25.2B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.4B
Genmab (GNMSF)$16B
Genmab (GMAB)$15.7B
Illumina (ILMN)$15.2B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$11B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.3B
Moderna (MRNA)$9.6B
Verona Pharma American Depositary Share (VRNA)$9.1B
Bio-Techne Corp (TECH)$8.9B
Exact Sciences (EXAS)$8.7B
Halozyme Therapeutics (HALO)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B